novo oral glp-1 FDA approves first-ever for weight loss Novo Nordisk fights back with

Regardless of which version is prescribed, the side effect profileincluding the potential for constipation and subsequent rectal bleedingremains similar because the active ingredient (the GLP-1 agonist) functions the same way in the body

PMCID: PMC6271067.

What the evidence supports No

Make sure that you are drinking as many fluids as possible to combat this

Polycystic ovary syndrome (PCOS) and its associated insulin resistance can add another layer of difficulty in achieving weight loss

These results suggest that autophagy is activated in RGCs of EAAC1 and GLAST KO mice, and NAC treatment suppresses autophagy in EAAC1 KO mice, but not in GLAST KO mice